ATE382356T1 - Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung - Google Patents

Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung

Info

Publication number
ATE382356T1
ATE382356T1 AT03764245T AT03764245T ATE382356T1 AT E382356 T1 ATE382356 T1 AT E382356T1 AT 03764245 T AT03764245 T AT 03764245T AT 03764245 T AT03764245 T AT 03764245T AT E382356 T1 ATE382356 T1 AT E382356T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
composition containing
cancer treatment
derivatives
containing estetrol
Prior art date
Application number
AT03764245T
Other languages
English (en)
Inventor
Bennink Herman Coelingh
Evert Bunschoten
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of ATE382356T1 publication Critical patent/ATE382356T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT03764245T 2002-07-12 2003-07-11 Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung ATE382356T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077812 2002-07-12
EP03075435 2003-02-14

Publications (1)

Publication Number Publication Date
ATE382356T1 true ATE382356T1 (de) 2008-01-15

Family

ID=30116907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03764245T ATE382356T1 (de) 2002-07-12 2003-07-11 Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung

Country Status (13)

Country Link
US (2) US9034854B2 (de)
EP (1) EP1526856B1 (de)
CN (1) CN100374116C (de)
AT (1) ATE382356T1 (de)
AU (1) AU2003253506A1 (de)
CA (1) CA2492287C (de)
CY (1) CY1107906T1 (de)
DE (1) DE60318447T2 (de)
DK (1) DK1526856T3 (de)
ES (1) ES2299730T3 (de)
PT (1) PT1526856E (de)
SI (1) SI1526856T1 (de)
WO (1) WO2004006936A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2492287C (en) * 2002-07-12 2011-12-13 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
DE102007032468A1 (de) * 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten
KR101957937B1 (ko) 2011-06-01 2019-03-14 에스테트라 에스.피.알.엘. 에스테트롤 중간체의 제조 방법
BR112013030830B1 (pt) 2011-06-01 2019-12-03 Estetra S A processo para a preparação de um composto de fórmula (i) e processo de preparação de estetrol
EP2383279A1 (de) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Herstellungsverfahren für Esterol
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
US9988417B2 (en) 2013-09-18 2018-06-05 Crystal Pharma, S.A.U. Process for the preparation of estetrol
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
ES2877186T3 (es) * 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
ES2877476T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
WO2019211322A1 (en) * 2018-05-02 2019-11-07 Mithra Pharmaceuticals S.A. Treatment of advanced estrogen receptor positive breast cancer
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2336434A1 (de) 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336433A1 (de) 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) * 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
AU2103495A (en) 1994-08-04 1996-03-04 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
EP0994718B1 (de) 1997-06-20 2005-08-17 Akzo Nobel N.V. Gonadotropin releasing hormon antagonist
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
EP1171091A1 (de) 1999-04-16 2002-01-16 Jenapharm GmbH & Co. KG Pharmazeutische oder kosmetische zusammensetzungen zur lokalen, intradermalen applikation von estrogenen
US7273932B1 (en) 1999-05-28 2007-09-25 The University Of Cincinnati Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20020012710A1 (en) * 1999-11-29 2002-01-31 Rimonest Ltd. Pomegranate products useful in improving health and methods of use thereof
CA2408935A1 (en) 2000-05-12 2001-11-15 Halina Offner Method of treating immune pathologies with low dose estrogen
US20040192598A1 (en) * 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
WO2002074315A1 (de) * 2001-03-21 2002-09-26 Schering Aktiengesellschaft Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (de) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie
ATE350041T1 (de) * 2001-05-18 2007-01-15 Pantarhei Bioscience Bv Pharmaceutishe zusammensetzung für die hormonersatztherapie
US6593321B2 (en) * 2001-06-11 2003-07-15 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
CA2492287C (en) * 2002-07-12 2011-12-13 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
AU2003274823A1 (en) * 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
EP1624878B1 (de) * 2003-05-22 2006-09-27 Pantarhei Bioscience B.V. Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen

Also Published As

Publication number Publication date
CA2492287C (en) 2011-12-13
EP1526856B1 (de) 2008-01-02
EP1526856A1 (de) 2005-05-04
CA2492287A1 (en) 2004-01-22
DE60318447T2 (de) 2009-01-02
DK1526856T3 (da) 2008-03-10
SI1526856T1 (sl) 2008-04-30
DE60318447D1 (de) 2008-02-14
US9034854B2 (en) 2015-05-19
US10201611B2 (en) 2019-02-12
ES2299730T3 (es) 2008-06-01
CN100374116C (zh) 2008-03-12
PT1526856E (pt) 2008-04-11
CY1107906T1 (el) 2013-09-04
WO2004006936A1 (en) 2004-01-22
WO2004006936A8 (en) 2005-03-03
US20150133413A1 (en) 2015-05-14
CN1681513A (zh) 2005-10-12
US20060063723A1 (en) 2006-03-23
AU2003253506A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
ATE380552T1 (de) Pharmazeutische zusammensetzung enthältend estetrolderivate und anwendung in der krebsbehandlung
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
HUP0303271A2 (hu) Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
WO2007149406A8 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
DE60318237D1 (de) Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol
EE9900288A (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
AR053977A1 (es) Composiciones farmaceuticas con enmascaramiento de sabor
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
IL150953A0 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
EP1503748A4 (de) Arzneimittel zur linderung durch taxan induzierte neurotoxizität
WO2005041936A3 (en) Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
JO2492B1 (en) A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
ZA200605900B (en) Glycosylated steroid derivatives with anti-migratory activity
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer
BRPI0416247A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
PE20021138A1 (es) Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la prostata

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1526856

Country of ref document: EP

REN Ceased due to non-payment of the annual fee